In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to unlock even greater value for Gilead as it advances ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.

TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD ...

TEANECK, N.J. - Cognizant Technology Solutions (NASDAQ:CTSH) Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...